Observation on the efficacy of TPO receptor agonists and platelet transfusion in chemotherapy-induced thrombocytopenia in malignant tumors

Abstract

Abstract Objective To observe the clinical efficacy of TPO receptor agonists and platelet transfusion in chemotherapy-induced thrombocytopenia in malignant tumors. Methods Clinical data from 120 patients with malignant tumors who developed thrombocytopenia following chemotherapy at our hospital were retrospectively collected and randomly divided into three groups: A, B, and C, with 40 patients in each group. Group A was treated with a TPO receptor agonist (avatrombopag), group B received autologous platelet transfusion, and group C received a combination of both treatments. The clinical efficacy of the three groups was compared, including platelet levels at different time points during treatment, platelet recovery time (time to reach 0.05), while the effective rate in group C was significantly higher than that in groups A and B (P 0.05). However, the time for these parameters in group C was significantly shorter than in groups A and B (P 0.05), whereas group C had significantly higher levels compared to groups A and B (P 0.05). However, group C had significantly lower APTT and higher FIB levels compared to groups A and B (P 0.05). Conclusion Autologous platelet transfusion and TPO receptor agonists are effective clinical methods for treating chemotherapy-induced thrombocytopenia. The combined use of both treatments yields better therapeutic results.

Keywords

• Malignant tumors
• Chemotherapy-induced thrombocytopenia
• TPO receptor agonist
• Autologous platelet transfusion
• Platelet count